HIV prevention in developed countries

Lancet

Volumn 348, Issue 9035, 1996, Pages 1143-1148

  Coates, Thomas J ^a   Aggleton, Peter ⁱ   Gutzwiller, Felix ^b   Jarlais, Don Des ^c   Kihara, Masahiro ^d   Kippax, Susan ^e   Schechter, Martin ^f,g   Van De Hoek, J Anneke R ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d KANAGAWA CANCER CENTER   (Japan)

^e MACQUARIE UNIVERSITY   (Australia)

^f ST PAUL S HOSPITAL   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h MUNICIPAL HEALTH SERVICE   (Netherlands)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

BISEXUALITY; BLOOD TRANSFUSION; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDUSTRIALIZATION; INTRAVENOUS DRUG ABUSE; POLITICS; PRIORITY JOURNAL; REVIEW; SAFETY; SEXUAL BEHAVIOR; SEXUALITY; VERTICAL TRANSMISSION;

EID: 0030603339     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)02307-0     Document Type: Review

References (50)

1. Lurie P, Bishaw M, Chesney MAet al. Ethical, behavioral and social aspects of HIV vaccine trials in developing countries. JAMA. 271:1994;295-301.
2. Stryker J, Coates TJ, Haynes-Sanstad K, Shriver M, Makadon HJ. HIV prevention: looking back, looking ahead. JAMA 1995; 273: 1143-48.
3. Des Jarlais DC, Hagan H, Friedman SR, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995; 274: 1226-31.
4. Coates TJ, Faigle M, Koijane J, Stall R. Does HIV prevention work among men who have sex with men? Report prepared for the Office of Technology Assessment, US Congress, 1995.
5. Choi KH, Coates TJ. Prevention of HIV infection. AIDS 1994; 8: 1371-89.
6. Dubois-Arber F, Paccaud F. Assessing AIDS-HIV prevention: What do we know in Europe? Soz Preventimed 1994; 37 (suppl 1): S3-13.
7. AIDS Epidemiology Group, Department of Preventive and Social Medicine, University of Otago Medical School: AIDS-New Zealand 1995; 26 (August).
8. National Centre in HIV Epidemiology and Clinical Research. Australian HIV Surveillance Report, 1995: 11, no 3.
9. European Centre for the Epidemiological Monitoring of AIDS. AIDS surveillance in Europe. Quarterly report number 43. Saint-Maurice, France: Hospital National de Saint-Maurice, Sept 30, 1994.
10. van Ameijden EJC, van den Hoek JAR, van Haastrecht HJA, Coutinho RA. The harm reduction approach and risk factors for human immunodeficiency virus seroconversion in injecting drug users, Amsterdam. Am J Epidemiol 1992; 136: 236-43.
11. Romano N, Vitale F, Alesi DR, et al. The changing pattern of HIV type I infection in intravenous drug users: Results of a six-year seroprevalence study in Palermo, Italy. Am J Epidemiol 1992; 135: 1189-96.
12. Nicolosi A, Leslie MLC, Molinari S. Incidence and prevalence trends of HIV infection in intravenous drug users attending treatment centres in Milan and Northern Italy, 1986-90. J Aquir Immune Defic Syndr 1992; 5: 365-73.
13. Zaccarelli M, Rezza G, Girai E. Monitoring trends in injecting drug users: an Italian experience. AIDS 1990; 4: 1007-10.
14. Peters AD, Reid MM, Griffin SG. Edinburgh drug users: are the injecting and sharing less. AIDS 1994; 8: 521-28.
15. Broers B, Junet C, Gabriel V, et al. Slow down of HIV epidemic among IDUs in Geneva, Switzerland. X International Conference on AIDS/V STD World Congress, Yokohama, August, 1994 (abstr PC0141).
16. Rezza G, Rota MC, Buning E, et al. Assessing HIV prevention among injecting drug users in the European community countries: a review. Soz Preventimed 1994; 37 (suppl): S61-78.
17. WHO Regional Office for Europe. The Global Programme on AIDS in the European Region, 1994 and 1995.
18. Surveillance Update: AIDS in Canada, Quarterly Report, 1995. Ottawa: HIV/AIDS Division, Laboratory Centre for Disease Control, Health Canada, 1995.
19. Hogg RS, Craib KJP, Willoughby BC, et al. Sociodemographic correlates for risk taking behavior among seronegative men. Can J Public Health 1993; 84: 423-26.
20. Rekart ML. Trends in HIV seroprevalence among street-involved persons in Vancouver, Canada, 1988-1992. IX International Conference on AIDS, Berlin, 1993 (Abstr).
21. First 500 000 cases - United States, 1995. Morbid Mortal Wkly Rec 1995; 44: 849-53.
22. Battjes RJ, Pickens RW, Brown LS HIV infection and AIDS risk behaviors among injecting drug users entering methadone treatment: an update. J Acquir Immune Defic Syndr. 10:1995;90-96.
23. Rosenberg PS, Biggar RJ, Goedert JJ. Scope of the AIDS epidemic in the United States. Science 1995; 270: 1322-75.
24. Hogg RS, Strathdee SA, Craib KJP, et al. Lowe socioeconomic status and shorter survival following HIV infection. Lancet 1994; 344: 1120-24.
25. Osmond DH, Page K, Wiley J, et al. HIV infection in homosexual and bisexual men 18 to 29 years of age: The San Francisco Young Men's Health Study. Am J Public Health 1994; 84: 1933-37.
26. Wellings K, Wadsworth J, Johnson AM, et al. Provision of sex education and early sexual experience: the relation examined. BMJ 1995; 311: 417-20.
27. Francis D, Chin J. The prevention of acquired immunodeficiency syndrome in the United States. J AMA 1987; 257: 1357-66.
28. van Ameijden EJC, Watters JK, van den Hoek JAR, Coutinho R. Interventions among injecting drug users: do they work? AIDS 1995; 9 (Suppl A): S75-84.
29. Bajos N, Wadsworth J, Ducot B, et al. Sexual behavior and HIV epidemiology: Comparative analysis in France and Britain. AIDS 1995; 9: 735-43.
30. Catania JA, Binson D, Dolcini MM, et al. Risk factors for HIV and other sexually transmitted diseases and prevention practices among US heterosexual adults: Changes from 1990 to 1992. Am J Public Health 1995; 85: 1492-99.
31. Lehmann P, Hauser D, Somaini B, Gutzwiller F. Campaign against AIDS in Switzerland: Evaluation of a nationwide educational programme. BMJ 1987; ii: 1118-20.
32. Stall R. How to lose the fight against AIDS among gay men. BMJ 1994; 309: 585-86.
33. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1992; 270: 474-78.
34. Hanvelt R, Ruedy NS, Hogg RS, et al. Indirect costs of HIV/AIDS mortality in Canada. AIDS 1994; 8: F7-11.
35. Kahn JG. The cost-effectiveness of HIV prevention targeting: how much more bang for the buck? Presented at targeted and universal approaches to reducing the risk of HIV transmission, New York, 1994.
36. Kegeles SM, Hays RB, Coates TJ. The Mpowerment project: a community-level HIV prevention intervention for young gay and bisexual men. Am J Publ Hlth (in press).
37. Des Jarlais DC, Padian NS, Winkelstein W. Targeted HIV-prevention programs. N Engl J Med 1994; 331: 1451-53.
38. Temmerman M, Ndinya-Achola J, Ambani J, Piot P. The right not to know HIV-test results. Lancet 1995; 345: 969-70.
39. Berrios DC, Hearst N, Coates TJ, et al. HIV antibody testing among those at risk for infection: The National AIDS Behavioral Surveys. JAMA 1993; 270: 1576-80.
40. Jacques JA, Koopman JS, Simon CP, Longini IM Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994; 7: 1169-84.
41. Stall R, Ekstrand M, Pollack L, McKusick L, Coates TJ. Relapse from safer sex: the next challenge for AIDS prevention efforts. J Acquir Immune Defic Syndr 1990; 3: 1181-87.
42. Ramsay S. English HIV and AIDS projections made. Lancet. 347:1996;109.
43. von Griensven GJP, de Vroome EMM, Goudsmit J, Coutinho RA. Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. BMJ 1989; 298: 218-21.
44. Sweat M, Dennison J. Reducing HIV incidence in developing countries with structural and environmental interventions. AIDS 1995; 9 (suppl A): S251-57.
45. Oakley A, Fullerton D, Holland J, et al. Sexual health education interventions for young people: a methodological review. BMJ 1995; 310: 158-62.
46. Susser M. The tribulation of trials - interventions in communities. Am J Public Health 1995; 2: 156-59.
47. Canadian AIDS Society. Doing it in the 90s: what you said. Ottawa: Canadian AIDS Society, 1993.
48. Canadian AIDS Society. Gaily forward. Ottawa: Canadian AIDS Society, 1993.
49. Valdiserri RO, Aultman TV, Curran JW Community planning: a national strategy to improve HIV prevention programs. J Community Health. 20:1995;87-100.
50. Lurie P, Hintzen P, Lowe RA. Socioeconomic obstacles to HIV prevention and treatment in developing countries: the roles of International Monetary Fund and the World Bank. AIDS 1995; 9: 539-46.